Who Are We?
XBiotech’s True Human™ antibody candidates are actually derived from donors with natural human immunity. No other marketed antibody product— including “humanized” and so-called “fully human"—are actually derived from natural human immunity.
Clinical Research
Discover our extraordinary innovation and success.
News Updates
Nov 1, 2024
XBiotech Has Non-clinical Data for a Novel Shingles Therapy Ready for IND SubmissionXBiotech announces the completion of non-clinical data and is preparing to submit Investigational New Drug (IND) application for their new Unmetix™ cocktail.
Oct 11, 2024
Phase II Portion for Natrunix™ Trifluridine/Tipiracil (TASKIN) Study OngoingSubjects continue to be enrolled in the Phase II part of TASKIN study, where they are receiving 1000mg of XBiotech’s True Human antibody Natrunix as part of their treatment for advanced colorectal cancer.
Sep 19, 2024
XBiotech Completes Successful FDA GLP InspectionDuring September 16, 2024 - September 19, 2024 the U.S. Food and Drug Administration (FDA) conducted an inspection as part of FDA's Bioresearch Monitoring Program.
Press releases
Technology
Harnessing natural human antibody immunity—an intuitive approach to a new generation of medicines.
State-of-the-art made simple. Engineered, designed and developed at XBiotech.
Pipeline
Our pipeline addresses a wide range of unmet medical needs.
Modern medicine should help patients feel better, not worse. At XBiotech, we believe in the Hippocratic principle of "do no harm." We believe this is inherent to the innovative True Human™ antibody medicines we are developing. True Human™ antibodies move beyond the idea that effective medicines must come with toxicity or harmful side effects.
By utilizing the body’s natural immune system, XBiotech develops therapies that help you heal and feel better.
